Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 20/20 | 0.62 |
| ▸ | CYP11B1 | P15538 | 17/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL428457 | 0.83 | CYP11B2 (0.71) | CYP11B2CYP11B1CYP3A4 | |
| SCHEMBL17896652 | 0.83 | CYP11B2 (0.53) | CYP11B2CYP11B1CYP3A4 | |
| SCHEMBL17896698 | 0.83 | CYP11B2 (0.60) | CYP11B2CYP11B1CYP3A4 | |
| SCHEMBL17896610 | 0.82 | CYP11B2 (0.53) | CYP11B2CYP11B1 | |
| SCHEMBL17896615 | 0.80 | CYP11B2 (0.68) | CYP11B2CYP11B1CYP3A4 | |
| SCHEMBL431913 | 0.80 | CYP11B2 (0.67) | CYP11B2CYP11B1CYP3A4 | |
| SCHEMBL31412053 | 0.79 | CYP11B2 (0.74) | CYP11B2CYP11B1 | |
| SCHEMBL20337766 | 0.79 | CYP11B2 (0.74) | CYP11B2CYP11B1 | |
| SCHEMBL17896606 | 0.79 | CYP11B2 (0.66) | CYP11B2CYP11B1 | |
| SCHEMBL17896608 | 0.79 | CYP11B2 (0.66) | CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382226-B2 | Aldosterone synthase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382226-B2 | Aldosterone synthase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-07-05 | — | — | US | disclosed |
| WO-2012012478-A1 | ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-01-26 | — | — | WO | disclosed |